LAX.SH
JAGSONPAL PHARMACEUTICALS·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
210.86
-3.24%52W Range
Market Cap
₹1,390.78 Cr
Traded: ₹1.40 Cr (0.10%) 0.0x
Free Float: ₹269.95 Cr (0.52% of FF traded)
Volume · 60D trend
65.52 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +12.0% | +17.0% | +17.0% | -- | -- | Stable |
| Return | +31.0% | +26.0% | +8.0% | -20.0% | -- | Decelerating |
| Profit | +30.0% | +21.0% | +16.0% | -- | +10.0% | Decelerating |
| Sales | +7.0% | +9.0% | +7.0% | -- | +4.0% | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82 | 64 | 73 | 74 | 76 | 59 | 74 | 75 | 61 | 43 | 47 | 58 | 60 | 55 |
| Expenses | 65 | 53 | 57 | 58 | 61 | 50 | 58 | 58 | 51 | 41 | 44 | 49 | 52 | 50 |
| Operating Profit | 17 | 11 | 16 | 16 | 14 | 9 | 16 | 16 | 10 | 3 | 3 | 8 | 9 | 5 |
| Other Income | 3 | 3 | 1 | 3 | 3 | 3 | 26 | 2 | -2 | 2 | 3 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 18 | 12 | 15 | 17 | 14 | 9 | 39 | 15 | 7 | 5 | 5 | 10 | 10 | 7 |
| Tax % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 24.0% | 17.0% | 25.0% | 25.0% | 22.0% | 25.0% | 25.0% | 26.0% | 23.5% |
| Net Profit | 13 | 9 | 11 | 13 | 11 | 7 | 32 | 11 | 5 | 4 | 4 | 7 | 7 | 6 |
| Exceptional Items | -- | 0 | -2 | 0 | 0 | -0 | 23 | 0 | -3 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 2.0 | 1.3 | 1.6 | 1.9 | 1.6 | 1.0 | 4.8 | 1.7 | 0.8 | 0.5 | 0.6 | 1.1 | 1.1 | 0.8 |
| Sales Growth (YoY) | -- | 9.6% | -1.5% | -0.3% | 23.1% | 34.6% | 56.7% | 29.1% | 2.1% | -21.6% | -21.5% | -4.5% | -0.7% | 8.2% |
| Sales Growth (QoQ) | -- | -12.0% | -2.0% | -1.5% | 29.1% | -20.9% | -0.9% | 21.6% | 41.3% | -7.9% | -18.3% | -3.9% | 8.5% | -- |
| OP Growth (YoY) | 21.4% | 22.2% | 0.0% | 0.0% | 40.0% | 200.0% | 433.3% | 100.0% | 11.1% | -44.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | 54.5% | -31.3% | 0.0% | 14.3% | 55.6% | -43.8% | 0.0% | 60.0% | 233.3% | 0.0% | -62.5% | -11.1% | 65.4% | -- |
| Profit Growth (YoY) | -- | 30.0% | -8.4% | 9.7% | 38.6% | 89.9% | 244.4% | 53.4% | 4.1% | -36.6% | -49.2% | -28.2% | 56.8% | 1706.5% |
| EPS Growth (YoY) | -- | 32.3% | -66.0% | 9.3% | 100.0% | 83.3% | 703.3% | 51.8% | -28.9% | -36.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -20.1% | -13.2% | 16.7% | 63.6% | -79.5% | 178.6% | 113.6% | 50.0% | -10.0% | -47.4% | 0.0% | 34.1% | -- |
| OP Margin | -- | 17.4% | 22.3% | 22.1% | 18.8% | 14.9% | 21.4% | 21.8% | 16.7% | 6.1% | 7.2% | 14.5% | 14.3% | 9.8% |
| Net Margin | -- | 13.6% | 15.0% | 16.9% | 14.3% | 11.2% | 43.2% | 15.3% | 8.7% | 8.2% | 8.4% | 12.9% | 12.4% | 10.1% |
| Material Cost % | -- | 37.0% | 36.3% | 36.6% | 35.6% | 37.1% | 35.8% | 34.7% | 36.3% | 40.6% | 41.4% | 36.2% | 36.7% | 40.3% |
| Employee Cost % | -- | 24.2% | 24.1% | 24.4% | 25.7% | 28.3% | 24.5% | 25.3% | 27.9% | 32.0% | 30.3% | 20.2% | 29.8% | 30.9% |
| P/S | 4.73 | 5.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 30.83 | 35.68 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.04 | 5.50 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of Analysts/Investors Conference Call
Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Financial ....
Certificate in terms of Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026
Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026.
Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022
Newspaper Advertisement regarding transfer of Shares to IEPF and Notice of loss of share Certificate
Press Release on Acquisition of Wellness Portfolio of Group pharmaceuticals Limited
Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited.
Voting Result and scrutinizer Report of 47th Annual General Meeting.
Summary of Proceedings of 47th Annual General Meeting.
Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting
Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26
BRSR for the Financial year ended March 31, 2026
Annual report for Financial Year 2025-26
Letter providing a web link of annual report 2025-26 to members.
Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022
Newspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18, 2026
Unaudited results along with its Limited Review Report for the quarter ended June 30, 2026
Corporate Action- Record Date for dividend Purpose: September 04, 2026
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company, as a ....
Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the unaudited Financial ....
Updates on Acquisition of Aequitas Healthcare Private Limited.
Allotment of 94,000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022.
Updates on Acquisition of Aequitas Healthcare Private Limited
Updates on Acquisition of Aequitas Healthcare Private Limited.
Compliance Certificate under Reg 74(5) of SEBI(DP) Regulations, 2018
Press Release on acquisition of Aequitas Healthcare Private Limited.
Acquisition of Aequitas Healthcare Private Limited
Closure of Trading window for the quarter ended June 30, 2026
Appointment of Mr. Anil Kumar Matai (DIN: 03122865) as an Additional Director in the category of Non-Executive Independent Director.
Appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an Additional Director in the category of Non-Executive Independent Director.
press release relating to appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an additional director in the category of Non-Executive Independent Director.
Extinguishment of 16,00,000 Equity Shares of Jagsonpal Pharmaceuticals Limited.
Please find enclosed Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026
Centrum Broking Ltd ("Manager to the Buyback") has submitted to BSE a copy of Post Buyback Public Announcement for the attention of Equity Shareholders / Beneficial Owners of Equity Shares ....
Submission of copy of Post Buy Back Public Advertisement related to Buy back of shares of Company.
Resignation of an Independent Director.
Newspaper Publication regarding dispatch of Letter of Offer of Buy Back to the shareholders of the Company
Submission of Letter of Offer for Buy- Back upto 16,00,000 Equity Shares at price of INR-250/- per share amounting to INR-40,00,00,000/-
Earning Call Transcript for meeting held on April 28, 2026
Submission of Public Announcement pertaining to Buy back of Shares of Company published in the newspaper along with Board and Shareholder Resolution
Newspaper Advertisement- Extract of Audited Financial Results for FY 26
Audio Recording of Jagsonpal Pharmaceuticals Limited Q4 FY26 Earnings Conference Call on April 28, 2026 at 3:00 P.M
Intimation for grant of Employee Stock Options
Voting Result of Postal Ballot along with Scrutinizer Report.
Voting Result of Postal Ballot for approval of Buy Back of Equity Shares.
Press Release on approval of Buy Back of Equity Shares of Company
Outcome of Board Meeting held on April 27, 2026 along with Audited (Standalone) Financial Results for the quarter and year ended March 31, 2026
Press Release for Audited Financial Results for the quarter and year ended March 31, 2026
Recommendation of Dividend for the Financial Year ended March 31, 2026
Annual Reports
15Credit Ratings
6Concalls
19Jan 2026
31 Jan 2026Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025Jul 2025
31 Jul 2025May 2025
31 May 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Oct 2024
31 Oct 2024Aug 2024
31 Aug 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2022
28 Feb 2022Held by ETFs
1 ETFs hold JAGSNPHARM · sorted by weight
Held by Mutual Funds
1 schemes hold JAGSNPHARM · sorted by weight